TSE:4502Pharmaceuticals
Why Takeda (TSE:4502) Is Up 6.3% After Positive Trial Data for IgA Nephropathy and Dengue Vaccine
Earlier this month, Takeda Pharmaceutical announced positive interim results from its Phase 1b study of mezagitamab in IgA nephropathy and confirmed the completion of a pivotal 7-year Phase 3 trial for its dengue vaccine QDENGA, with new data supporting the safety and sustained efficacy of both therapies.
These advancements highlight Takeda's progress in developing treatments for high-need diseases and reinforce its ongoing commitment to innovation in rare disease and vaccine research.
We'll...